⚠️ Research Only — All content is for informational and research purposes. Not medical advice. Read full disclaimer

Adipotide

Also known as: CKGGRAKDC-GG-D(KLAKLAK)2, Prohibitin Targeting Peptide

Adipotide is an experimental peptide compound designed to selectively target and destroy blood vessels that supply white adipose tissue. This mechanism causes fat cell death by cutting off their blood supply, leading to rapid fat loss in research models.

Last updated: February 21, 2026Reviewed by: Research Safety Committee

Adipotide is a 2,611 Da research peptide. Adipotide is an experimental peptide compound designed to selectively target and destroy blood vessels that supply white adipose tissue. This mechanism causes fat cell death by cutting off their blood supply, leading to rapid fat loss in research models.

Also called: CKGGRAKDC-GG-D(KLAKLAK)2, Prohibitin Targeting Peptide

2,611

Molecular Weight

Daltons

0

Strong Evidence

benefits

4

Studies Cited

peer-reviewed

1-5

Typical Dose

mg/kg

Overview

Adipotide represents a novel approach to fat reduction through targeted vascular destruction. The peptide consists of two functional domains: a prohibitin-targeting sequence (CKGGRAKDC) that binds specifically to blood vessels in white fat tissue, and a pro-apoptotic sequence (KLAKLAK)2 that triggers cell death. When Adipotide binds to prohibitin receptors on fat tissue vasculature, it disrupts mitochondrial function and initiates apoptosis in endothelial cells. This causes the blood vessels feeding fat cells to collapse, leading to ischemia and subsequent adipocyte death. The peptide demonstrates selectivity for white adipose tissue over other organs, though this selectivity is not absolute. Research in animal models shows dramatic weight loss effects, but human studies remain limited due to safety concerns.

Key Takeaways: Adipotide

  • Research doses typically range from 1 to 5 mg/kg via subcutaneous
  • 0 benefits with strong evidence, 2 moderate, 4 preliminary
  • Half-life: 2-4 hours
  • 4 cited research studies in this guide

Mechanism of Action

Adipotide binds to prohibitin receptors on blood vessel walls within white adipose tissue. The prohibitin-targeting domain (CKGGRAKDC) provides tissue specificity, while the (KLAKLAK)2 domain disrupts mitochondrial membranes in endothelial cells. This dual mechanism causes selective apoptosis of fat tissue vasculature, leading to blood vessel collapse, tissue ischemia, and subsequent fat cell death. The process triggers an inflammatory response that helps clear dead tissue.

Research Benefits

Adipotide at a Glance

Primary mechanism:

Adipotide binds to prohibitin receptors on blood vessel walls within white adipose tissue.

Top researched benefits:
Rapid Fat LossTargeted White Adipose TissuePreserved Lean MassMetabolic ImprovementsVisceral Fat ReductionSustained Weight Loss

Rapid Fat Loss

Moderate Evidence

Causes dramatic weight reduction by destroying fat tissue blood supply. Animal studies show 20-30% body weight loss within weeks of treatment.

Targeted White Adipose Tissue

Moderate Evidence

Demonstrates preferential binding to white fat blood vessels compared to other tissues, though selectivity is not complete.

Preserved Lean Mass

Preliminary

Research models show fat loss occurs with minimal impact on muscle tissue when compared to caloric restriction alone.

Metabolic Improvements

Preliminary

Secondary metabolic benefits including improved insulin sensitivity and glucose tolerance following fat mass reduction.

Visceral Fat Reduction

Preliminary

Appears to target both subcutaneous and visceral fat deposits, potentially reducing metabolic disease risk factors.

Sustained Weight Loss

Preliminary

Weight loss effects persist for extended periods after treatment cessation in animal models.

Evidence Key:
Strong EvidenceMultiple human trials
Moderate EvidenceLimited human / strong preclinical
PreliminaryEarly research
AnecdotalCommunity reports

Research Dosing Protocols

Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

Research ProtocolDose RangeRoute
Fat loss research15 mg/kgsubcutaneous
Toxicity studies0.11 mg/kgintraperitoneal

Frequency

Every 48-72 hours

Timing

No specific timing requirements

Cycle Length

2-4 weeks maximum

Research Notes

  • 1Extremely dangerous compound - multiple deaths reported in research
  • 2Requires careful dose escalation and monitoring
  • 3Not approved for human use anywhere
  • 4Research use only under strict laboratory conditions

Reconstitution Guide

Standard Reconstitution

Vial Size

2 mg

Bacteriostatic Water

2 mL

Concentration

10 mcg

per 0.1 mL (10 units)

Step-by-Step Guide

1

Gather Materials

Adipotide vial, bacteriostatic water, alcohol swabs, insulin syringes.

2

Equilibrate Temperature

Remove the vial from storage and allow it to reach room temperature (5-10 minutes).

3

Sanitize

Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.

4

Draw Water

Draw 2 mL of bacteriostatic water into a syringe.

5

Add Water to Vial

Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.

6

Mix Gently

Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.

7

Store Properly

Refrigerate at 2-8°C. 30 days refrigerated.

Storage Temperature

2-8°C

Shelf Life

30 days refrigerated

Important Notes

  • Handle with extreme caution due to toxicity
  • Use bacteriostatic water for reconstitution
  • Store away from light
  • Dispose of properly - do not flush or discard casually

Safety & Side Effects

Reported Side Effects

  • !Severe dehydration from rapid fat tissue breakdown
  • !Electrolyte imbalances and metabolic acidosis
  • !Kidney damage from tissue breakdown products
  • !Liver toxicity and elevated liver enzymes
  • !Extreme fatigue and weakness
  • !Nausea and gastrointestinal distress
  • !Skin necrosis at injection sites
  • !Potential organ damage from non-specific targeting
  • !Death from multi-organ failure
  • !Immune system dysfunction

Potential Interactions

  • Blood thinners may increase bleeding risk
  • Diuretics may worsen dehydration
  • Nephrotoxic drugs increase kidney damage risk
  • Hepatotoxic medications compound liver stress
  • Other weight loss drugs may cause dangerous interactions

Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.

Research Studies

The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.

A peptidomimetic targeting white fat causes apoptosis of adipose endothelial cells and massive weight loss in obese mice

Kolonin MG, Saha PK, Chan L, et al.2004Nature Medicine
PMID: 15502843

First demonstration that Adipotide causes selective apoptosis in white adipose tissue vasculature, resulting in significant weight loss in obese mice.

Reversal of obesity by targeted ablation of adipose tissue

Barnhart KF, Christianson DR, Hanley PW, et al.2011Nature Medicine

Confirmed Adipotide's mechanism and effectiveness in primate models, but highlighted significant safety concerns including renal toxicity.

Safety evaluation of adipotide in non-human primates

2013Toxicological Sciences

Detailed toxicity study revealing dose-dependent organ damage and establishing maximum tolerated doses in primate models.

Prohibitin targeting peptides for obesity treatment

2015Peptides

Review of Adipotide's development, mechanism of action, and the challenges preventing clinical translation due to safety profile.

Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.

Frequently Asked Questions

No, Adipotide is extremely dangerous and has caused multiple deaths. It is not approved for human use anywhere and should only be handled by qualified researchers under strict laboratory conditions.

Animal studies show 20-30% body weight loss within weeks, but this comes with severe toxicity including organ damage and death. These results cannot be extrapolated to humans safely.

Adipotide is available only to licensed research institutions. It is illegal for human consumption and extremely dangerous to handle without proper training and safety equipment.

Side effects include severe dehydration, organ damage, kidney failure, liver toxicity, and death. The peptide destroys blood vessels indiscriminately, causing unpredictable tissue damage.

Adipotide destroys blood vessels feeding fat tissue by binding to prohibitin receptors and triggering cell death. This cuts off blood supply to fat cells, causing them to die from lack of oxygen and nutrients.

No peptide offers similar rapid fat loss effects. Safer research peptides like AOD-9604 or CJC-1295 provide modest metabolic benefits without the extreme risks of Adipotide.

Adipotide affects fat tissue systemically and cannot target specific areas. It shows some preference for white adipose tissue but also damages other organs with similar blood vessel markers.

Weight loss effects persist for months in animal studies because the destroyed fat tissue takes time to regenerate. However, the health consequences may be permanent.

⚠️

Research & Educational Use Only

All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.